Li, Ying
Dang, Lin
Lv, Chengzhi
Lin, Bingjiang
Tao, Juan
Yu, Nan
Deng, Ya
Wang, Huiping
Kang, Xiaojing
Qin, Hui
Chen, Rong
Li, Jinnan
Liang, Yunsheng
Liang, Yanhua
Shi, Yuling http://orcid.org/0000-0002-1273-7881
Funding for this research was provided by:
Eli Lilly and Company
Article History
Accepted: 18 March 2024
First Online: 30 April 2024
Declarations
:
: This study was funded by Eli Lilly and Company.
: R.C. and J.L. are employees of Eli Lilly China. The other authors have no conflicts of interest to declare.
: This study was conducted with respect for the individual participants according to the protocol, the World Medical Association Declaration of Helsinki, the ICH-GCP guideline, and applicable local regulatory requirements of each participating region. The study was approved by Independent Ethics Committees at each study center (see electronic supplementary material, Table ).
: All patients provided written, informed consent prior to participating in the study.
: Not applicable.
: Data can be made available from the corresponding author on reasonable request.
: Not applicable.
: L.Y. and D.L. contributed to design of the work, acquisition of data for the work, interpretation of data for the work and critical revision of the work for important intellectual content. S.Y.L. contributed to conception of the work, acquisition of data for the work, interpretation of data for the work and critical revision of the work for important intellectual content. L.Y.S., L.Y.H., L.C.Z., L.B.J., T.J., Y.N., D.Y., W.H.P., K.X.J., and Q.H. contributed to acquisition of data for the work and critical revision of the work for important intellectual content. C.R. and L.J.N. contributed to interpretation of data for the work and critical revision of the work for important intellectual content. All authors read and approved the final version.